ECP
VIR icon

Empyrean Capital Partners’s Vir Biotechnology VIR Stock Holding History

Empyrean Capital Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Sell
114,000
-413,800
-78% -$3.94M 0.04% 111
2026
Q1 		$4.73M Buy
+527,800
New +$4.21M 0.15% 99

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Empyrean Capital Partners's VIR Position: Q2 2026 in Review

Empyrean Capital Partners reduced its Vir Biotechnology (VIR) stake by 78% in Q2 2026, selling an estimated $3.94M and leaving 114,000 shares worth $1.16M. The position accounts for 0.04% of the portfolio, ranked #111.

Empyrean Capital Partners first reported a position in VIR in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.73M in Q1 2026. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Empyrean Capital Partners held 114,000 shares of Vir Biotechnology worth $1.16M as of Q2 2026.
  • Empyrean Capital Partners sold 413,800 Vir Biotechnology shares in Q2 2026, an estimated $3.94M.
  • Vir Biotechnology made up 0.04% of Empyrean Capital Partners's portfolio in Q2 2026, its #111 holding.
  • Empyrean Capital Partners first reported a position in Vir Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • Empyrean Capital Partners's Vir Biotechnology position peaked at $4.73M in Q1 2026.
  • 238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Empyrean Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.